Table of Contents |
guest 2025-07-11 |
Welcome!
Two NIDDK programs, one focused on Type 1 Diabetes (see NIH grant RFA here) and one focused on Obesity (see NIH grant RFA here) funded three different groups with the goal of developing and disseminating
targeted mass spectrometry assays for the diagnosis and monitoring of Type 1 Diabetes and Obesity. While the funding sources are separate, we felt there were obvious synergies in these efforts and formed TaMADOR with the goal of leveraging each other's capabilities and strengths.
Part of the project? Click HERE for internal resources (agendas, meeting logs, etc). TAMADOR Publications
![]() |
Quantifying Proteins in Plasma to Democratize Personalized Medicine for Patients with Type 1 Diabetes |
![]() |
Robust Mass Spectrometric Protein/Peptide Assays for Type 1 Diabetes Clinical Applications |
![]() |
Design and Validation of Easy-to-Adopt Mass Spectrometry Assays of Importance to Obesity |
|
Multiplex Mass Spectrometric Protein Assays for Precise Monitoring of the Pathophysiology of Obesity |
April 10, 2025, 8:00 AM-5:00 PM
Neuroscience Center
Register at: Type 1 Diabetes Biomarkers Meeting
The precise and accurate quantification of proteins and peptides that are involved in diabetes pathogenesis will help facilitate research into disease mechanisms and ultimately improve the diagnosis, prognosis, and therapeutic management of patients with diabetes. NIDDK recently funded several projects that aim to use targeted mass spectrometry to quantify human plasma/serum proteins and peptides of interest to the obesity and diabetes clinical research community. During this symposium, members of the Targeted Mass spectrometry Assays for Diabetes and Obesity Research (TaMADOR) consortium will provide an overview of the recent advances toward this goal, with a special focus on type 1 diabetes. Other speakers will highlight the importance of biomarkers and their harmonization in the study of diabetes and the care of patients with this important chronic disease.
During this symposium, members of the Targeted Mass spectrometry Assays for Diabetes and Obesity Research (TaMADOR) consortium will provide an overview of the recent advances toward this goal, with a special focus on type 1 diabetes. Other speakers will highlight the importance of biomarkers and their harmonization in the study of diabetes and the care of patients with this important chronic disease.
7:30-8:00 am |
Light breakfast |
8:00-8:10 am |
Salvatore Sechi, Ph.D., NIDDK/NIH History and purpose of TaMADOR |
8:10-8:20 am |
Will Cefalu, M.D. NIDDK/NIH Welcome and Introduction |
8:20-9:00 am |
Marian Rewers, M.D., Ph.D., University of Colorado An Overview of Islet Autoantibody Testing Methods |
9:00-9:25 am |
Michael MacCoss, Ph.D., University of Washington Plasma Proteomics for the Assessment of Patient Response to Therapy |
9:25-9:50 am |
Lorenz Nierves, Ph.D., PNNL Mass Spectrometry-based discovery of prohormone processing products as potential novel biomarkers |
9:50-10:00 am |
Coffee Break |
10:00-10:35 am |
Kuanysh Kabytaev, Ph.D., University of Missouri Standardization of C-peptide/Insulin |
10:35-11:00 pm |
Jun Qu, Ph.D., University of Buffalo A multiplex assay for proinsulin proteoforms: assay development and optimization |
11:00-11:25 pm |
Katrina Forrest, University of Washington Progress Toward Novel Assays for Alternative Proglucagon Fragments |
11:25-12:00 pm |
Carmella Evans-Molina, M.D., Ph.D., University of Indiana Biomarkers in Clinical Diabetes Research |
12:00-12:45 pm |
Lunch |
12:45-1:10 pm |
Weijun Qian, Ph.D., PNNL Exploratory assessment of proinsulin proteoforms as biomarkers of beta cell stress in T1D |
1:10-1:35 pm |
Andy Hoofnagle, MD PhD, University of Washington Quantification of Proinsulin in Human Plasma |
1:35-2:10 pm |
Rob Fitzgerald, Ph.D., University of California, San Diego A Clinical Lab Perspective of a Successful Biomarker |
2:10-2:25 pm |
Coffee Break |
2:25-2:50 pm |
Weijun Qian, Ph.D., PNNL; and Jun Qu, Ph.D., University of Buffalo Assessments of novel methods for biomarker discovery |
2:50-3:15 pm |
Jessica Becker, M.S., University of Washington Interlaboratory Transfer of a Novel Assay for Glucagon and Oxyntomodulin |
3:15-3:55 pm |
Bruce Verchere, Ph.D., University of British Columbia Islet prohormone processing: proIAPP forms as novel beta cell biomarkers in diabetes |
4:00-5:00 pm |
Closed: Expert Panel / Investigators meeting |
Program for the TaMADOR meeting in Seattle, Washington
Location: Brotman Auditorium, University of Washington South Lake Union Campus
Register at: https://diabetesmetabseminars.com/event/targeted-mass-spectrometry-assays-for-diabetes-and-obesity-research-tamador/
8:00
Breakfast in Lobby
8:30
NIDDK/NIH
History and Purpose of TaMADOR
8:45
University of Florida
Clinical Trials and Biomarkers
9:20
Benaroya Research Institute
Biomarkers in Type 1 Diabetes Research
9:55
Cedars-Sinai (Virtual)
Assessment of Obesity and Diabetes as Co-morbidities in Precision Health
10:20
Coffee Break in Lobby
10:30
University of Washington
The TaMADOR Consortium: Interlaboratory Transfer of a Combined Antibody-free Insulin/C-peptide Assay
10:55
University of Washington
Preparing for the Interlaboratory Transfer of a Novel Assay to Measure Glucagon and Oxyntomodulin
11:20
PNNL
LC-MS Assays for Specific Prohormone Proteoforms (Insulin and IAPP) Relevant to Type 1 Diabetes
11:45
University of Washington
Progress Toward a Proteolysis-peptide Immunoaffinity Enrichment-LC-MS/MS Assay for Proinsulin
12:10
Lunch in Lobby
1:00
NIH Clinical Center
Hemoglobin A1c as a Clinical Biomarker
1:35
University of Washington
Past, Present, and Future of T1D Biomarkers
2:10
PNNL
LC-MS Assays for Obesity Biomarkers
2:35
University of Washington
Using Mass Spectrometry for Monitoring Patient Response to Therapy
3:00
PNNL & University of Buffalo
Top-down Proteomics for Elucidating Cellular Prohormone Proteoforms and Novel Analytical Approaches for Enhancing Sensitivity
Marriott Bethesda Downtown, MD
December 1, 2022
Multiplex quantification of protein/peptide hormones and biomarkers involved in obesity and diabetes will facilitate translational scientific research. Unfortunately, most assays today rely exclusively on antibodies and often there are no widely accepted guidelines or standardized methods to determine the validity of these reagents. Furthermore, many recent publications have highlighted the limitations of many commercial antibodies including failure to detect the intended target. The rigor and reproducibility of many assays commonly used by researchers in the field of diabetes and obesity could be substantially improved applying Mass Spectrometry (MS) instead of relying only on antibodies. Within last decade, major improvements in instrumentation and data handling have made MS–based targeted proteomics a highly reproducible methodology for detecting and quantifying proteins and peptides.
The NIDDK recently funded several projects that aim to use targeted MS approaches for quantifying human plasma/serum proteins and peptides of main interest to the obesity and diabetes research community.
This meeting will focus on advances made by the TArgeted Mass spectrometry Assays for Diabetes and Obesity Research (TAMADOR) pseudo-consortium and possible future directions. This includes insulin, pro-insulin, c-peptide, glucagon, adiponectin, leptin, secretin, and GLP-1, to name a few.
WHEN: December 1, 2022
WHERE: Marriott Bethesda Downtown at Marriott HQ | website »
7707 Woodmont Avenue, Bethesda, Maryland, USA, 20814 | map »
Tel: +1 301-276-7707
Book your group rate for The Cedars-Sinai Obesity Grant Meeting Room Block
Event Summary:
Start Date: Wednesday, November 30, 2022 3:30PM-6:00PM
Location: Marriott Grand Ballroom
Thursday, December 1, 2022
Location: Marriott Grand Ballroom
End Date: Friday, December 2, 2022
Hotel(s) offering your special group rate:
Marriott Bethesda Downtown at Marriott HQ for 199 USD per night
Book your group rate for The Cedars-Sinai Obesity Grant Meeting Room Block
ZOOM OPTION: This meeting will be in-person but the option to participate remotely via Zoom will be provided to all registered participants the day before the meeting.
NOTE: COVID Protocol: CDC, Montgomery County Info Portal, County Policy, and Hotel regulations and guidance will be followed. Masks optional but recommended. Subject to change without notice.
For logistic questions contact:
Kim Douglas
Kim.douglas@cshs.org
TEL: (310) 654-3947
For scientific content contact:
Dr. Salvatore Sechi
Sechi@nih.gov
TEL: (301)-594-8814
Pre-Meeting
November 30, 2022
3:30PM-6:00PM
Location: Marriott Grand Ballroom
18:30 Dinner in Bethesda (TaMADOR Investigators, NIDDK, Advisory panel members), Location: TBD
December 1, 2022
Location: Marriott Grand Ballroom
7:30-8:00 Coffee and Registration
8:00-8:15 Introduction and Logistics by Dr. Salvatore Sechi, NIDDK
8:15-8:25 Welcome and meeting opening by Dr. William Cefalu, Director DEM, NIDDK
8:25-9:10 Keynote Speaker - Mari Demarco, Ph.D., University of British Columbia
Session I: Targeted Mass Spectrometric Assays in Type 1 Diabetes
09:10-09:30 A novel assay to assess the endogenous role of glucagon in glucose homeostasis
Jess Becker, MLS(ASCP), M.S., University of Washington (15’ talks + 5’ Q&A)
09:30-09:50 Using novel antibodies for the measurement of pro-insulin in serum
Michelle Emrick, Ph.D., University of Washington (15’ talks + 5’ Q&A)
9:50-10:10 Coffee Break
10:10-10:40 Keynote Speaker - David A. D'Alessio, MD, Duke University
10:40-11:10 Development and transferability of a combined C-peptide and insulin assay for the study of diabetes.
Andy Hoofnagle, MD/PhD, University of Washington (25’ talks + 5’ Q&A)
11:10-11:30 A vendor neutral platform for sharing interlaboratory data to accelerate diabetes and obesity research.
Mike MacCoss, Ph.D., University of Washington (15’ talks + 5’ Q&A)
11:30-12:50 Lunch Break (on your own)
Session II: Targeted Mass Spectrometric Assays in Obesity Research
12:50-13:20 Keynote Speaker - Rudolph Leibel, MD, Columbia University
13:30-13:50 Health surveillance assay: 60 protein targeted assays for monitoring disease co-morbidities.
Annie Moradian, PhD, Cedars-Sinai Medical Center (15’ talks + 5’ Q&A)
13:50-14:10 Quantitation of proteolyzed peptide hormones involved in the regulation of obesity and diabetes.
Simion Kreimer, PhD, Cedars-Sinai Medical Center (15’ talks + 5’ Q&A)
14:10-14:30 A multiplexed immunoaffinity-MS assay for sensitive detection of adiponectin, leptin, and resistin in obesity samples.
Jie Pu, Ph.D., University at Buffalo
14:30-14:50 Coffee Break
14:50-15:10 A highly multiplexed assay for quantifying a panel of 42 obesity-associated markers in blood plasma/serum.
Tai-Du Lin, Ph.D., Pacific Northwest National Laboratory (15’ talks + 5’ Q&A)
15:10-15:30 Novel methods for the detection of low abundance markers in serum without the need of antibody reagents.
Wei-Jun Qian, Ph.D., Pacific Northwest National Laboratory,
and Jun Qu, Ph.D., University at Buffalo (15’ talks + 5’ Q&A)
15:30-16:30 Discussion on clinical translation of Mass Spectrometry based assays.
Panelists: Jennifer Van Eyk (Cedars-Sinai Medical Center), Kimia Sobhani (Cedars-Sinai Medical Center), Michael MacCoss (University of Washington), Andy Hoofnagle (University of Washington), Weijun Qian (PNNL), Jun Qu (University at Buffalo).
Introduction and moderation by Ravinder Singh (Mayo Clinic)
16:30 Meeting Adjourned
16:30-17:30 Meeting for PIs, NIDDK , and advisors only. (Grand Ballroom)
Advisors: Randie Little, University of Missouri; David Nathan, Harvard
Medical School; Rudolph Leibel, Columbia University; Philipp Sherer, UT
Southwestern (not present at this meeting); James Delany, Advent Health
Research Institute; Ravinder Singh, Mayo Clinic; Robert Fitzgerald, UCSD.
TaMADOR Meetings
DK137097
| Perez-Riverol Y, Bittremieux W, Noble WS, Martens L, Bilbao A, Lazear MR, Grüning B, Katz DS, MacCoss MJ, Dai C, Eng JK, Bouwmeester R, Shortreed MR, Audain E, Sachsenberg T, Van Goey J, Wallmann G, Wen B, Käll L, Fondrie WE. Open-Source and FAIR Research Software for Proteomics. J Proteome Res. 2025 May 2;24(5):2222-2234. doi: 10.1021/acs.jproteome.4c01079. Epub 2025 Apr 23. PMID: 40267229; PMCID: PMC12053954.DK124019
| Fu Q, Johnson C, Inker LA, Van Eyk JE. A targeted LC MS/MS assay of a health surveillance panel and its application to chronic kidney disease. bioRxiv [Preprint]. 2025 Mar 16:2025.03.14.643399. doi: 10.1101/2025.03.14.643399. PMID: 40161722; PMCID: PMC11952516.DK137097
| Schweppe DK, Beliveau BJ, Hoofnagle AN. Molecular Phenotyping With Proteomics. JAMA. 2025 Mar 11;333(10):898-899. doi: 10.1001/jama.2024.28089. PMID: 39883454; PMCID: PMC12053805.DK137097
| Li J, Hatten-Beck M, Lee JKY, Hoofnagle AN. Insights into insulin analog cross-reactivity: a comparative study of Siemens Atellica and LC-MS/MS. Endocrine. 2025 Jan;87(1):79-84. doi: 10.1007/s12020-024-03970-6. Epub 2024 Jul 19. PMID: 39030378; PMCID: PMC11739172.DK124019
| Fu Q, Vegesna M, Sundararaman N, Damoc E, Arrey TN, Pashkova A, Mengesha E, Debbas P, Joung S, Li D, Cheng S, Braun J, McGovern DPB, Murray CI, Xuan Y, Van Eyk JE. A Proteomics Pipeline for Generating Clinical Grade Biomarker Candidates from Data-Independent Acquisition Mass Spectrometry (DIA-MS) Discovery. Angew Chem Int Ed Engl. 2024 Dec 20;63(52):e202409446. doi: 10.1002/anie.202409446. Epub 2024 Nov 11. PMID: 39432331.DK137097
| Remes PM, Jacob CC, Heil LR, Shulman N, MacLean BX, MacCoss MJ. Hybrid Quadrupole Mass Filter-Radial Ejection Linear Ion Trap and Intelligent Data Acquisition Enable Highly Multiplex Targeted Proteomics. J Proteome Res. 2024 Dec 6;23(12):5476-5486. doi: 10.1021/acs.jproteome.4c00599. Epub 2024 Oct 30. PMID: 39475161; PMCID: PMC11956834.DK137113
| Sarkar S, Zheng X, Clair GC, Kwon YM, You Y, Swensen AC, Webb-Robertson BM, Nakayasu ES, Qian WJ, Metz TO. Exploring new frontiers in type 1 diabetes through advanced mass-spectrometry-based molecular measurements. Trends Mol Med. 2024 Dec;30(12):1137-1151. doi: 10.1016/j.molmed.2024.07.009. Epub 2024 Aug 15. PMID: 39152082; PMCID: PMC11631641.DK124019
| Hendricks NG, Bhosale SD, Keoseyan AJ, Ortiz J, Stotland A, Seyedmohammad S, Nguyen CDL, Bui J, Moradian A, Mockus SM, Van Eyk JE. An inflection point in high-throughput proteomics with Orbitrap Astral: analysis of biofluids, cells, and tissues. bioRxiv [Preprint]. 2024 Apr 27:2024.04.26.591396. doi: 10.1101/2024.04.26.591396. Update in: J Proteome Res. 2024 Sep 6;23(9):4163-4169. doi: 10.1021/acs.jproteome.4c00384. PMID: 38712179; PMCID: PMC11071456.DK137113
DK124020
| Shen Q, Pu J, Xue C, Zhang M, Qu Y, Huo S, Belford M, Maxey C, Wijeratne N, Martins C, Peterman S, Qian WJ, Boeser C, Qu J. A Trapping-Micro-LC-FAIMS/dCV-MS Strategy for Ultrasensitive and Robust Targeted Quantification of Protein Drugs and Biomarkers. Anal Chem. 2024 Aug 13;96(32):13140-13149. doi: 10.1021/acs.analchem.4c01888. Epub 2024 Jul 30. PMID: 39078725; PMCID: PMC11984221.DK124019
| Karpov OA, Stotland A, Raedschelders K, Chazarin B, Ai L, Murray CI, Van Eyk JE. Proteomics of the heart. Physiol Rev. 2024 Jul 1;104(3):931-982. doi: 10.1152/physrev.00026.2023. Epub 2024 Feb 1. PMID: 38300522; PMCID: PMC11381016.DK137097
| Plubell DL, Remes PM, Wu CC, Jacob CC, Merrihew GE, Hsu C, Shulman N, MacLean BX, Heil L, Poston K, Montine T, MacCoss MJ. Development of highly multiplex targeted proteomics assays in biofluids using the Stellar mass spectrometer. bioRxiv [Preprint]. 2024 Jun 11:2024.06.04.597431. doi: 10.1101/2024.06.04.597431. PMID: 38895256; PMCID: PMC11185584.DK124019
| Jiang Y, DeBord D, Vitrac H, Stewart J, Haghani A, Van Eyk JE, Fert-Bober J, Meyer JG. The Future of Proteomics is Up in the Air: Can Ion Mobility Replace Liquid Chromatography for High Throughput Proteomics? J Proteome Res. 2024 Jun 7;23(6):1871-1882. doi: 10.1021/acs.jproteome.4c00248. Epub 2024 May 7. PMID: 38713528; PMCID: PMC11161313.DK121289
DK137097
| Moradian A, Goonatilleke E, Lin TT, Hatten-Beck M, Emrick M, Schepmoes AA, Fillmore TL, MacCoss MJ, Sechi S, Sobhani K, Little R, Kabytaev K, van Eyk JE, Qian WJ, Hoofnagle AN. Interlaboratory Comparison of Antibody-Free LC-MS/MS Measurements of C-peptide and Insulin. Clin Chem. 2024 Jun 3;70(6):855-864. doi: 10.1093/clinchem/hvae034. PMID: 38549041; PMCID: PMC12052497.DK137097
| Plubell DL, Huang E, Spencer SE, Poston K, Montine TJ, MacCoss MJ. Data Independent Acquisition to Inform the Development of Targeted Proteomics Assays Using a Triple Quadrupole Mass Spectrometer. bioRxiv [Preprint]. 2024 May 30:2024.05.29.596554. doi: 10.1101/2024.05.29.596554. PMID: 38853953; PMCID: PMC11160738.DK121289
DK137097
| Wu CC, Tsantilas KA, Park J, Plubell D, Sanders JA, Naicker P, Govender I, Buthelezi S, Stoychev S, Jordaan J, Merrihew G, Huang E, Parker ED, Riffle M, Hoofnagle AN, Noble WS, Poston KL, Montine TJ, MacCoss MJ. Mag-Net: Rapid enrichment of membrane-bound particles enables high coverage quantitative analysis of the plasma proteome. bioRxiv [Preprint]. 2024 Apr 2:2023.06.10.544439. doi: 10.1101/2023.06.10.544439. PMID: 38617345; PMCID: PMC11014469.DK121289
DK137097
| Gray SM, Goonatilleke E, Emrick MA, Becker JO, Hoofnagle AN, Stefanovski D, He W, Zhang G, Tong J, Campbell J, D'Alessio DA. High Doses of Exogenous Glucagon Stimulate Insulin Secretion and Reduce Insulin Clearance in Healthy Humans. Diabetes. 2024 Mar 1;73(3):412-425. doi: 10.2337/db23-0201. PMID: 38015721; PMCID: PMC10882148.DK121289
DK137097
| Vázquez Torres S, Leung PJY, Venkatesh P, Lutz ID, Hink F, Huynh HH, Becker J, Yeh AH, Juergens D, Bennett NR, Hoofnagle AN, Huang E, MacCoss MJ, Expòsit M, Lee GR, Bera AK, Kang A, De La Cruz J, Levine PM, Li X, Lamb M, Gerben SR, Murray A, Heine P, Korkmaz EN, Nivala J, Stewart L, Watson JL, Rogers JM, Baker D. De novo design of high-affinity binders of bioactive helical peptides. Nature. 2024 Feb;626(7998):435-442. doi: 10.1038/s41586-023-06953-1. Epub 2023 Dec 18. PMID: 38109936; PMCID: PMC10849960.DK124020
DK137113
| Fulcher JM, Swensen AC, Chen YC, Verchere CB, Petyuk VA, Qian WJ. Top-Down Proteomics of Mouse Islets With Beta Cell CPE Deletion Reveals Molecular Details in Prohormone Processing. Endocrinology. 2023 Nov 2;164(12):bqad160. doi: 10.1210/endocr/bqad160. PMID: 37967211; PMCID: PMC10650973.DK124020
| Moon S, Alsarkhi L, Lin TT, Inoue R, Tahiri A, Colson C, Cai W, Shirakawa J, Qian WJ, Zhao JY, El Ouaamari A. Transcriptome and secretome profiling of sensory neurons reveals sex differences in pathways relevant to insulin sensing and insulin secretion. FASEB J. 2023 Oct;37(10):e23185. doi: 10.1096/fj.202300941R. PMID: 37695721; PMCID: PMC10503313.DK124020
| Chen YC, Taylor AJ, Fulcher JM, Swensen AC, Dai XQ, Komba M, Wrightson KLC, Fok K, Patterson AE, Klein Geltink RI, MacDonald PE, Qian WJ, Verchere CB. Deletion of Carboxypeptidase E in β-Cells Disrupts Proinsulin Processing but Does Not Lead to Spontaneous Development of Diabetes in Mice. Diabetes. 2023 Sep 1;72(9):1277-1288. doi: 10.2337/db22-0945. PMID: 37364047; PMCID: PMC10450824.DK124020
| Nakayasu ES, Bramer LM, Ansong C, Schepmoes AA, Fillmore TL, Gritsenko MA, Clauss TR, Gao Y, Piehowski PD, Stanfill BA, Engel DW, Orton DJ, Moore RJ, Qian WJ, Sechi S, Frohnert BI, Toppari J, Ziegler AG, Lernmark Å, Hagopian W, Akolkar B, Smith RD, Rewers MJ, Webb-Robertson BM, Metz TO; TEDDY Study Group. Plasma protein biomarkers predict the development of persistent autoantibodies and type 1 diabetes 6 months prior to the onset of autoimmunity. Cell Rep Med. 2023 Jul 18;4(7):101093. doi: 10.1016/j.xcrm.2023.101093. Epub 2023 Jun 29. PMID: 37390828; PMCID: PMC10394168.DK124020
| Wang X, Niu J, Qian S, Shen S, Straubinger RM, Qu J. Species-Deconvolved Proteomics for In Situ Investigation of Tumor-Stroma Interactions after Treatment of Pancreatic Cancer Patient-Derived Xenografts with Combined Gemcitabine and Paclitaxel. J Proteome Res. 2023 Jul 7;22(7):2436-2449. doi: 10.1021/acs.jproteome.3c00164. Epub 2023 Jun 13. PMID: 37311110; PMCID: PMC10561664.DK124020
| Kitata RB, Hu LY, Lin TT, Nicora CD, Fillmore TL, Nie S, Hudson RD, Liu T, Leach RJ, Liu AY, Qian WJ, Shi T. Targeted Mass Spectrometry Assays for Specific Quantification of Urinary proPSA Isoforms. J Proteome Res. 2023 Mar 3;22(3):942-950. doi: 10.1021/acs.jproteome.2c00745. Epub 2023 Jan 10. PMID: 36626706; PMCID: PMC10072162.DK124020
| Shen S, Wang X, Zhu X, Rasam S, Ma M, Huo S, Qian S, Zhang M, Qu M, Hu C, Jin L, Tian Y, Sethi S, Poulsen D, Wang J, Tu C, Qu J. High-quality and robust protein quantification in large clinical/pharmaceutical cohorts with IonStar proteomics investigation. Nat Protoc. 2023 Mar;18(3):700-731. doi: 10.1038/s41596-022-00780-w. Epub 2022 Dec 9. PMID: 36494494; PMCID: PMC10673696.DK124020
| Lin TT, Zhang T, Kitata RB, Liu T, Smith RD, Qian WJ, Shi T. Mass spectrometry-based targeted proteomics for analysis of protein mutations. Mass Spectrom Rev. 2023 Mar;42(2):796-821. doi: 10.1002/mas.21741. Epub 2021 Oct 31. PMID: 34719806; PMCID: PMC9054944.DK124020
| Dakup PP, Feng S, Shi T, Jacobs JM, Wiley HS, Qian WJ. Targeted Quantification of Protein Phosphorylation and Its Contributions towards Mathematical Modeling of Signaling Pathways. Molecules. 2023 Jan 23;28(3):1143. doi: 10.3390/molecules28031143. PMID: 36770810; PMCID: PMC9919559.DK124020
| Pu J, Xue C, Huo S, Shen Q, Qu Y, Yang X, An B, Angel TE, Chen Z, Mehl JT, Tang H, Yang E, Sikorski TW, Qu J. Highly Accurate and Robust Absolute Quantification of Target Proteins in Formalin-Fixed Paraffin-Embedded (FFPE) Tissues by LC-MS. Anal Chem. 2023 Jan 17;95(2):924-934. doi: 10.1021/acs.analchem.2c03473. Epub 2022 Dec 19. PMID: 36534410; PMCID: PMC10581745.DK121289
| Deutsch EW, Bandeira N, Perez-Riverol Y, Sharma V, Carver JJ, Mendoza L, Kundu DJ, Wang S, Bandla C, Kamatchinathan S, Hewapathirana S, Pullman BS, Wertz J, Sun Z, Kawano S, Okuda S, Watanabe Y, MacLean B, MacCoss MJ, Zhu Y, Ishihama Y, Vizcaíno JA. The ProteomeXchange consortium at 10 years: 2023 update. Nucleic Acids Res. 2023 Jan 6;51(D1):D1539-D1548. doi: 10.1093/nar/gkac1040. PMID: 36370099; PMCID: PMC9825490.DK137097
| Martinez TF, Lyons-Abbott S, Bookout AL, De Souza EV, Donaldson C, Vaughan JM, Lau C, Abramov A, Baquero AF, Baquero K, Friedrich D, Huard J, Davis R, Kim B, Koch T, Mercer AJ, Misquith A, Murray SA, Perry S, Pino LK, Sanford C, Simon A, Zhang Y, Zipp G, Bizarro CV, Shokhirev MN, Whittle AJ, Searle BC, MacCoss MJ, Saghatelian A, Barnes CA. Profiling mouse brown and white adipocytes to identify metabolically relevant small ORFs and functional microproteins. Cell Metab. 2023 Jan 3;35(1):166-183.e11. doi: 10.1016/j.cmet.2022.12.004. PMID: 36599300; PMCID: PMC9889109.DK124020
| Ma M, Huo S, Zhang M, Qian S, Zhu X, Pu J, Rasam S, Xue C, Shen S, An B, Wang J, Qu J. In-depth mapping of protein localizations in whole tissue by micro-scaffold assisted spatial proteomics (MASP). Nat Commun. 2022 Dec 14;13(1):7736. doi: 10.1038/s41467-022-35367-2. PMID: 36517484; PMCID: PMC9751300.DK124020
| Brasil BB, Masaji S, Martins BT, Jiang H, Song N, Athena A S, Lucas B, François M, Wei-Jun Q, Rohit KN, Ronald KC. Apolipoprotein C3 and circulating mediators of preadipocyte proliferation in states of lipodystrophy. Mol Metab. 2022 Oct;64:101572. doi: 10.1016/j.molmet.2022.101572. Epub 2022 Aug 11. PMID: 35964946; PMCID: PMC9418991.DK121289
| Foulon N, Goonatilleke E, MacCoss MJ, Emrick MA, Hoofnagle AN. Multiplexed quantification of insulin and C-peptide by LC-MS/MS without the use of antibodies. J Mass Spectrom Adv Clin Lab. 2022 Jun 10;25:19-26. doi: 10.1016/j.jmsacl.2022.06.003. PMID: 35734440; PMCID: PMC9207678.DK121289
| Heil LR, Fondrie WE, McGann CD, Federation AJ, Noble WS, MacCoss MJ, Keich U. Building Spectral Libraries from Narrow-Window Data-Independent Acquisition Mass Spectrometry Data. J Proteome Res. 2022 Jun 3;21(6):1382-1391. doi: 10.1021/acs.jproteome.1c00895. Epub 2022 May 12. PMID: 35549345; PMCID: PMC9204981.DK121289
| Phipps WS, Greene DN, Pflaum H, Laha TJ, Dickerson JA, Irvine J, Merrill AE, Ranjitkar P, Henderson CM, Hoofnagle AN. Small volume retinol binding protein measurement by liquid chromatography-tandem mass spectrometry. Clin Biochem. 2022 Jan;99:111-117. doi: 10.1016/j.clinbiochem.2021.10.005. Epub 2021 Oct 19. PMID: 34678307; PMCID: PMC8671195.DK124020
| Ye Y, Swensen AC, Wang Y, Kaushal M, Salamon D, Knoten A, Nicora CD, Marks L, Gaut JP, Vijayan A, Orton DJ, Mudd PA, Parikh CR, Qian WJ, O'Halloran JA, Piehowski PD, Jain S. A Pilot Study of Urine Proteomics in COVID-19-Associated Acute Kidney Injury. Kidney Int Rep. 2021 Dec;6(12):3064-3069. doi: 10.1016/j.ekir.2021.09.010. Epub 2021 Oct 7. PMID: 34642644; PMCID: PMC8494995.DK121289
| Martin K, Zhang T, Lin TT, Habowski AN, Zhao R, Tsai CF, Chrisler WB, Sontag RL, Orton DJ, Lu YJ, Rodland KD, Yang B, Liu T, Smith RD, Qian WJ, Waterman ML, Wiley HS, Shi T. Facile One-Pot Nanoproteomics for Label-Free Proteome Profiling of 50-1000 Mammalian Cells. J Proteome Res. 2021 Sep 3;20(9):4452-4461. doi: 10.1021/acs.jproteome.1c00403. Epub 2021 Aug 5. PMID: 34351778; PMCID: PMC8945255.DK124020
| Nakayasu ES, Gritsenko M, Piehowski PD, Gao Y, Orton DJ, Schepmoes AA, Fillmore TL, Frohnert BI, Rewers M, Krischer JP, Ansong C, Suchy-Dicey AM, Evans-Molina C, Qian WJ, Webb-Robertson BM, Metz TO. Tutorial: best practices and considerations for mass-spectrometry-based protein biomarker discovery and validation. Nat Protoc. 2021 Aug;16(8):3737-3760. doi: 10.1038/s41596-021-00566-6. Epub 2021 Jul 9. PMID: 34244696; PMCID: PMC8830262.DK124020
| Shen S, Li J, Huo S, Ma M, Zhu X, Rasam S, Duan X, Qu M, Titus MA, Qu J. Parallel, High-Quality Proteomic and Targeted Metabolomic Quantification Using Laser Capture Microdissected Tissues. Anal Chem. 2021 Jun 29;93(25):8711-8718. doi: 10.1021/acs.analchem.1c01026. Epub 2021 Jun 10. PMID: 34110778; PMCID: PMC10640922.DK124020
| Wang X, Jin L, Hu C, Shen S, Qian S, Ma M, Zhu X, Li F, Wang J, Tian Y, Qu J. Ultra-High-Resolution IonStar Strategy Enhancing Accuracy and Precision of MS1-Based Proteomics and an Extensive Comparison with State-of-the-Art SWATH-MS in Large-Cohort Quantification. Anal Chem. 2021 Mar 23;93(11):4884-4893. doi: 10.1021/acs.analchem.0c05002. Epub 2021 Mar 9. PMID: 33687211; PMCID: PMC10666926.DK121289
| Marcovina SM, Clouet-Foraison N, Koschinsky ML, Lowenthal MS, Orquillas A, Boffa MB, Hoofnagle AN, Vaisar T. Development of an LC-MS/MS Proposed Candidate Reference Method for the Standardization of Analytical Methods to Measure Lipoprotein(a). Clin Chem. 2021 Mar 1;67(3):490-499. doi: 10.1093/clinchem/hvaa324. PMID: 33517366; PMCID: PMC7935757.DK121289
| Owusu BY, Pflaum H, Garner R, Foulon N, Laha TJ, Hoofnagle AN. Development and Validation of a Novel LC-MS/MS Assay for C-Peptide in Human Serum. J Mass Spectrom Adv Clin Lab. 2021 Jan;19:1-6. doi: 10.1016/j.jmsacl.2020.12.001. Epub 2020 Dec 28. PMID: 34723236; PMCID: PMC8553002.DK124019
| Sundararaman N, Go J, Robinson AE, Mato JM, Lu SC, Van Eyk JE, Venkatraman V. PINE: An Automation Tool to Extract and Visualize Protein-Centric Functional Networks. J Am Soc Mass Spectrom. 2020 Jul 1;31(7):1410-1421. doi: 10.1021/jasms.0c00032. Epub 2020 Jun 11. PMID: 32463229; PMCID: PMC10362945.DK121289
| Pino LK, Searle BC, Yang HY, Hoofnagle AN, Noble WS, MacCoss MJ. Matrix-Matched Calibration Curves for Assessing Analytical Figures of Merit in Quantitative Proteomics. J Proteome Res. 2020 Mar 6;19(3):1147-1153. doi: 10.1021/acs.jproteome.9b00666. Epub 2020 Feb 24. PMID: 32037841; PMCID: PMC7175947.DK124019
| Van Eyk JE, Snyder MP. Precision Medicine: Role of Proteomics in Changing Clinical Management and Care. J Proteome Res. 2019 Jan 4;18(1):1-6. doi: 10.1021/acs.jproteome.8b00504. Epub 2018 Oct 22. PMID: 30296097; PMCID: PMC10372929.DK124019
| Van Eyk JE, Sobhani K. Precision Medicine. Circulation. 2018 Nov 13;138(20):2172-2174. doi: 10.1161/CIRCULATIONAHA.118.036781. PMID: 30571512; PMCID: PMC8260056.